Sensorion Achieves Key Regulatory Milestones for SENS-601 for GJB2-related Hearing Loss and Selects Program as Lead Gene Therapy Candidate

Sensorion Achieves Key Regulatory Milestones for SENS-601 for GJB2-related Hearing Loss and Selects Program as Lead Gene Therapy Candidate

Clinical trial applications for SENS-601 (GJB2-GT) filed in Canada and France with Fast Track procedure granted by the French agency (ANSM)

IND submission in the U.S. and submission in Australia targeted by year-end 2026

SENS-601 originated utilizing gene therapy platform co-developed with the Institut Pasteur, addresses GJB2-related hearing loss, the most common cause of genetic deafness

SENS-501 (OTOF-GT) discontinued and company resources focused on SENS-601; cash runway extended to the end of 2027